Participants
fungal infection, cancer, heart failure, human immunodeficiency virus, sepsis, hypersensitivity
SARS-COV-2 INFECTION, HUMAN IMMUNODEFICIENCY VIRUS, FUNGAL INFECTION, LIVER FAILURE, CANCER, HEART, HEART FAILURE, END-STAGE KIDNEY DISEASE, SEPTIC SHOCK, SEPSIS, HYPERSENSITIVITY
It was considered eligible to study participation patients aged 18–80 years hospitalized with SARS-CoV-2 infection, diagnosis confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) and symptoms starting within 14 days of the randomization date.Exclusion criteria included patients undergoing mechanical ventilation at randomization, pregnancy or lactation, known hypersensitivity to propolis, propolis use within the prior 30 days, active cancer, human immunodeficiency virus positivity, solid organ or bone marrow transplant, use of immunosuppressive drugs, bacterial or fungal infection at randomization, sepsis or septic shock, inability to administer medication orally or via a nasoenteral tube, known liver failure, advanced heart failure (New York Heart Association [NYHA] class III or IV) or end-stage kidney disease.